OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

I agree but the market seems to decide otherwise with sells outdoing buys by near 5 to 1 - Lets hope they are being collected for a big buyer. There is often a bit of tree shaking on a Friday

A lot of tree-shaking now...


Oxford Biomedica's phase III trial for cancer jab Trovax 'will not meet goals' - AFX

LONDON (Thomson Financial) - Oxford Biomedica Plc's cancer vaccination TroVax will not meet its defined goals in a late stage study for renal cancer, according to a key review board.

While the trial will continue, the Drug Safety Monitoring Board has ruled that there should be no more vaccinations administered.

Chief executive Mike McDonald said: 'This news is clearly disappointing. However, there is good reason to continue the study and potentially a late survival benefit for TroVax may still be demonstrated.'

The drug is being developed in partnership with Sanofi-Aventis SA.

Sold out a couple of weeks ago into SKP so no better off skp down 50% since I bought.

Of the two OXB Management is far better and focussed - but this blow may cause some heads to roll, although the progression of Trovax is still on-going. It's not as though OXB is a 1-product shop. It does mean we may see further falls as the trial unwinds. I have bought a few more as this is getting close to the cash-value. OXB bought another Oxford-based research Co abt a year ago and this should provide some additional products to undergo trials etc.etc.

Does anyone know if the US-trials are affected? -

Oxford Biomedica, the U.K. biotechnology company that is working with Sanofi-Aventis SA, had a record decline in London trading after saying its TroVax medicine won't meet the target of a kidney cancer study.

Oxford BioMedica fell 11 pence, or 59 percent, to 7.5 pence, giving the company a market value of 40.3 million pounds ($80.2 million). That's the biggest drop since the shares began trading in 1996. The stock has declined 71 percent this year.

Yes yes yes, I agree...that you say is fact - it's a nasty move for anyone with a million shares - not I . . . . . yet the Trial is continuing and as the ch Exec says:- ".... there is good reason to continue the study and potentially a late survival benefit for TroVax may still be demonstrated.'..."

Now, "he would say that"- - - springs to mind....yet this Friday RNS is not at all clear as to "why" the Trial is unsatisfactory - - - or "what went wrong", - and presumably we have to await further Data to establish if there is any real Value in Trovax.

I must say I'm very surprised as all earlier Trials indicated that not only was it good, it was ---very good.

Good luck.
I checked FT website and they are still reporting Feb.2008
- ah, happy days when the sp was close to 25p....

Its still valued at 40 million quid and no product ???

Bin bag job.

My Bin bag job was April.pure luck!

DIL, it is inconceivable that there is zero effect - how did it get to Phase iii?

This fall is still on-going, despite the continuation of TWO separate Trials. This is now trading below Cash, some say.
Let's watch it drop further, eh?
The danger is a Big Pharma will Bid for the Laboratory/Pipeline+ Cash.

ok - so now we are down at the bottom end - does anyone have any idea whats going on? can we expect a miracle along with a share price rally?

I understand the Trovax data is still being gathered, so no ann. soon.

There is little risk of takeover, this uncertainty -would stop any Due-dilligence in its tracks. . . . . this stock rests on Trovax being better than many may think, everything else is a bonus. Cash for 2-3 years I guess, maybe more.
It was my No 1, as everything looked in place....but then....

Are you a LT holder, . . . + did you go to their last AGM?

New bid offer from USA today, the board will have to issue another RNS today.

The Bid and "improved offer" from GeneThera is from a tiny company that has no chance of taking over OXB. OXB could buy them out ( why not- excellent ploy!) and hardly notice the difference in the OXB cash-pile.

I cannot imagine why GeneThera even considered it, unless they were backed by some finance house.....in which case we'd be told.

It's fanciful, IMHO and just shows that the Market is undervaluing OXB, since the sp (was) about the value of their cash.....shows how devastating a Drug-wobble is....YET - the Trovax Trial continues - make of that what you will, but I'm not conviniced it not still OK ( ie it will be successful). If so then all you punters will rue the day you didn't buy OXB at 5.5 pence for your ISA - let's suppose it reaches 75p - that's nearly a 15-bagger for a modest investment of say 2k......better choose the colour of your next Motor...only joking, we're years away.

HangonI have always had a good feeling about thesesold at a loss in Aprilcould have been a lot worse!still got a good gut feeling.especially at this pricesp acting with interest.no rampingis the product gamble to great..what is your honest gut feeling on a 1-10? My finger is hovering on the button.

HangonI have gone for it!still would like your gut feeling.

tabasco, I really do not know.
However, I'm still in - and bought a few (to av. Dn. at 8p+),
Financially they are sound, so they could buy-in some short-term eye-candy to divert the Market's focus. By widening their appeal their expertise with the FDA would be invaluable and they've been pretty smart with Sanofi- the money is Paid, even if Trovax "fails" -
We're not there yet, but then "earlier trials" would be shams and I can't see that being so. OXB messed-up the "end-points" - and that's their undoing. Seems rather severe.
Glad to read you're "in" again, did you benefit from the rise to 10p, or was that all you?
This is a risky Market and this is a risky stock, BUT I think there is value there - I just hope it's a lot more than current 10p - I suspect we could see 50p only if these Trials are Positive....but I prefer the acquisition route, even though it diverts ...at least it will give Management something to do while the Trials work-through (so it's not a Bad Plan, IMHO). Now is "probably the right time" to go a-buying; with many Bio's in the mire.

Hangon I have friends still in on this one and still optimisticthey have taken a hitand like you averaged downwhich is the way I playI have never made money on thesealthough missed the big drop by luckbought on the 18th august @ 11.20p there is something about the stock.think the percentage is in our favour at these levelsalthough product means high risk?

What a difference a day makes!

tabasco - yes indeedy - but even if Trovax proves worthless for its current treatment - there are yet other angles for it. I suspect that was why Sanofi wanted the technology -

These are "early days" for Gene therapy - it's cutting-edge stuff, I understand.

Also, OXB has other treatments, but you need to read-up for details...everyone is focussed on this Trial . . . . . and that has caused a big upset.
+Glad to read you're in at 11p - a small profit already, perhaps evens with charges/spread?
FWIW I'd wait, there is no real NEWS, and it's reaction (bounce), to over-selling . . . . may take a few months more to reach, say 15p . . .
...then any better news will let it ride-up 19p ( it doesn't like 20p!).....then it's anyone's guess...the Market might push hard, but I fear folks will sell at 25p - 35p (depending where their average is) . . . . missing any longer-term upsides.
BUT there are no g'tees here, it seems.....we've been badly shocked and that takes time to repair...oh deary.


I hope they widen their portfolio, spend some cash to create a broad business - - if it works they are sitting pretty - if not then they had their best shot.
PS Today's rise may be due to an Analysists meeting/presentation which could interest Institutions to invest further. Worth reading also Troval.com on the trials.

Genethera would not bid for Oxford Biomedica as it is not credible


LONDON, Sept 3 LONDON, Sept 3 (Reuters) - Genethera Inc , the US-based veterinary diagnostics company, announced Wednesday that it has decided not to proceed with an offer for Oxford BioMedica Plc .

The British biotech company last month spurned a 35 pence all-share takeover bid by Genethera -- pitched at a 300 percent premium at the time -- describing it as not credible.

Oxford BioMedica shares closed at 10.5 pence on Tuesday.

Following the rejection, the US company, which had a market capitalisation of $230,000 while Oxford BioMedica was worth 46.5 million pounds or $87 million at the time the offer was made, had said it was considering its options.